MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
about
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaHypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaClinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.TP53 mutation and survival in aggressive B cell lymphoma.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.Clinicopathological analysis of polyploid diffuse large B-cell lymphoma.Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics.Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
P2860
Q27853399-2700DD61-DBCA-4889-9AFB-F9B1544553EBQ33869257-D8FA3939-22CE-4F5E-ADE6-18A9B8CBD4DBQ34287747-AB7B3F38-A06F-4249-A6FB-68367DDA924DQ34654655-B1858B04-3BEF-4A0B-BDDC-DD23E1609E5AQ35742364-2135BC97-3856-4A0D-8811-D6E48AC1C441Q35742367-BE08844D-D218-4AA4-8655-F738A1E45A3BQ36681461-BBF94064-49E2-45D3-8DA4-A12108E58FC4Q38213115-E48A4ECE-9925-4FC5-8C3D-508DA8D56664Q38882112-C0F3EC5C-8DB0-46E4-BF79-041D591E3E27Q40160075-0092F237-ED91-4F3B-ADD7-B6EFB9D6811AQ40796551-E4EDCE93-3786-4893-899E-9FE668EAF8F9Q41507351-C8ED2195-4F87-4A1D-B099-1DD8AB4C0BEBQ45228677-4CF9A52D-E7D4-4209-AE2E-1600FF214812Q48108703-49E93EE2-2290-441E-AD13-5023F3E46B38Q52594128-9454034D-BEE1-4EBE-B721-7D3E8CBBC71CQ54977441-B1E04AA1-B23D-4C6F-8869-6EAE69C1B2F6Q55068347-F9EF3BAB-1857-4F73-9569-8145797C4E6CQ55476353-BA8EDCF8-7030-49F6-8EF4-F8107A2CA18CQ57759564-0EEB13C3-153B-4AFD-9ACE-DFF22EC8DDB7
P2860
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MDM2 phenotypic and genotypic ...... ximab-CHOP Consortium Program.
@en
MDM2 phenotypic and genotypic ...... ximab-CHOP Consortium Program.
@nl
type
label
MDM2 phenotypic and genotypic ...... ximab-CHOP Consortium Program.
@en
MDM2 phenotypic and genotypic ...... ximab-CHOP Consortium Program.
@nl
prefLabel
MDM2 phenotypic and genotypic ...... ximab-CHOP Consortium Program.
@en
MDM2 phenotypic and genotypic ...... ximab-CHOP Consortium Program.
@nl
P2093
P2860
P50
P1433
P1476
MDM2 phenotypic and genotypic ...... uximab-CHOP Consortium Program
@en
P2093
Andrés J M Ferreri
April Chiu
Carlo Visco
Carlos E Bueso-Ramos
Eric D Hsi
Ganiraju C Manyam
Jooryung Huh
Ken H Young
Kristy L Richards
L Jeffrey Medeiros
P2860
P304
P356
10.1182/BLOOD-2012-12-473702
P407
P50
P577
2013-08-27T00:00:00Z